Induction of secondary hyperalgesia in the area of non-degenerated TRPV1 positive nerve fiber branches

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00034965

Enrollment

Registered

2024-08-30

Start date

2024-10-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Studies on healthy volunteers for basic experimental research purposes

Interventions

Group 1: Two qutenza-patches 1.5x1.5cm (179mg capsaicin / 280cm²) with a distance of 1 cm in between and one placebo-patch 1.5x1.5cm at a distance of 5 cm from either qutenza-patch. Duration of applic

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: healthy

Exclusion criteria

Exclusion criteria: intake of anti-histaminergic medication

Design outcomes

Primary

Measure	Time frame
Endpoint: Changes in intensity of evoked sensation and skin reddening. Time point of assessment: immediately prior patch-application (d0), during patch administration at day1 and day4 (d1 and d4), weekly after patch removal for 12 weeks (d7-d14-d21-d28-d35-d42-d49-d56-d63-d70-d77-d84).	—

Secondary

Measure	Time frame
Changes in intensity of histamine-mediated itch (d4-d7-d14-d21-d28-d35-d42-d49-d56-d63-d70-d77-d84).	—

Countries

Germany

Contacts

Public ContactRoman Rukwied

Experimentelle Schmerzforschung MCTN der Medizinischen Fakultät Mannheim der Universität Heidelberg

roman.rukwied@medma.uni-heidelberg.de+49 621 383 3170

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026